Navigation Links
Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations
Date:7/21/2009

LAUSANNE, Switzerland, July 21 /PRNewswire/ -- Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, today announced that the Swiss agency for therapeutic products, Swissmedic, has issued a marketing authorisation for Moapar(R) 11.25mg, the first 3-month injectable formulation, prescribed for a reversible reduction of serum testosterone to the level of castration in adult men suffering from sexual deviations. Developed by Debiopharm, Moapar(R) contains a gonadotropin-releasing hormone (GnRH) agonist analogue.

"We are very pleased that Swissmedic has recognised the potential of treatment of sexual deviations with Moapar(R)," said Rolland-Yves Mauvernay, President and Founder of Debiopharm Group. "This is an important signal for us, as we move closer to providing an alternative treatment for this controversial disorder. It's a small market, but we feel that it's our duty to make this treatment available to the medical profession."

Debiopharm already received marketing authorisations and signed license agreements for the distribution of Salvacyl(R)/Moapar(R) in nine major European countries, including France, Germany, the United Kingdom, Sweden, Norway, Denmark, Belgium, the Netherlands and Finland. The product was launched earlier this year in Germany and Belgium. Initial contacts with potential distribution partners for the Swiss market have been made.

About Moapar(R)

In the treatment of sexual deviations in men, intra-muscular administration of Moapar(R) every 3 months, in combination with psychotherapy, presents an advantage over daily oral forms or intra-muscular weekly injections required with antiandrogens such as cyproterone acetate (CPA) and medroxyprogesterone acetate (MPA), and there are fewer side effects.

The approval is based on two studies showing that, combined with psychotherapy, regular injections of the active ingredient, triptorelin, over a period of eight months to seven years in male patients with sexual deviations demonstrated a good efficacy and safety profile. Triptorelin decreased serum testosterone to the level of castration in all patients. Concurrent with the decrease in testosterone levels, the treatment reduced deviant sexual behaviours in 35 of 36 patients with severe sexual deviations. In men who interrupted treatment, testosterone levels progressively returned to normal.

About Debiopharm Group

Debiopharm Group is a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs. It develops its products for global registration and maximum commercial potential. Once registered, the products are out-licensed to pharmaceutical partners for sales and marketing.

Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.

Founded in 1979 and headquartered in Lausanne, Switzerland, Debiopharm has developed four products with global combined sales in excess of US$2.6 billion in 2008.

For more information on Debiopharm Group, please visit: http://www.debiopharm.com.

    Debiopharm S.A. Contact:

    Maurice Wagner
    Director Corporate Affairs & Communication
    Tel.: +41(0)21-321-01-11
    Fax: +41(0)21-321-01-69
    mwagner@debiopharm.com

    Additional Media Contacts:

    In London:
    Maitland
    Brian Hudspith
    Tel: +44(0)20-7379-5151
    bhudspith@maitland.co.uk

    In New York:
    Russo Partners, LLC
    Martina Schwarzkopf, Ph.D.
    Account Executive
    Tel: +1-212-845-4292
    Fax: +1-212-845-4260
    martina.schwarzkopf@russopartnersllc.com


'/>"/>
SOURCE Debiopharm Group
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations
2. US FDA Grants Orphan Drug Status to Immtechs Pafuramidine for Treatment of African Sleeping Sickness
3. Chinese SFDA Grants Immtech Fast Track Status
4. Ethics Group Asks USAID Inspector General to Investigate Legality of Grants to Soros Groups
5. NTMir Announces Research Grants for Epidemiology and Household Water as Source of Infection
6. FDA Grants Approval to Extend U.S. Enrollment and Clinical Trial
7. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
8. FDA Grants Priority Review for ACIPHEX(R) (rabeprazole sodium) sNDA for Short-Term Treatment of GERD in Adolescents
9. FDA Grants Priority Review for PROMACTA(R) (eltrombopag)
10. FDA Grants NeoVistas Request to Expand CABERNET Trial to 30 Sites in the U.S.
11. FDA Grants Market Clearance for the LipiScan(TM) Coronary Imaging System Developed by InfraReDx, Inc. - A Novel Spectroscopy System for the Identification of Lipid Core Containing Plaques of Interest in the Coronary Arteries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... TUCSON, Ariz. , May 3, 2016  As ... twice contracted rheumatic fever, which damaged his heart. ... But by June 2013, Shepherd,s heart was ... days from death. On June 20, 2013, the ... temporary Total Artificial Heart (TAH-t). Like a heart transplant, ...
(Date:5/3/2016)... OSWEGO, Ore. , May 3, 2016 /PRNewswire/ ... endovascular medical technology, today announced Food and Drug ... cardiac resynchronization defibrillator that provides heart failure patients ... scans. Iperia devices also have remote monitoring with ... that adapts the heart rate in response to ...
(Date:5/3/2016)...   BIOTRONIK will be exhibiting and initiating ... implant at the Heart Rhythm Society,s 37 th ... Francisco . "Physicians and hospitals ... patient care and satisfaction possible. Part of that process ... tomorrow," said Marlou Janssen , President, BIOTRONIK, Inc. ...
Breaking Medicine Technology:
(Date:5/6/2016)... KING OF PRUSSIA, PA and LONDON, UK (PRWEB) , ... May ... ... continues to earn accolades for his success in changing the way the pharmaceutical industry ... Power 100 list of the world’s most influential people in pharma, and he was ...
(Date:5/6/2016)... ... 2016 , ... Featured cast and producers of the acclaimed ... the 2016 Learning Summit , June 12-15, in Paradise Valley, Arizona. , ... complicated family issues, financial difficulties, and other personal obstacles—are the stories of millions ...
(Date:5/6/2016)... ... 2016 , ... A wide variety of national pet product manufacturers, companies and brands will gather ... Wednesday, May 18 from noon to 8 p.m. at New York City’s Roger Smith Hotel. ... established home, garden, outdoor and safety pet products in today’s marketplace. , Petrend ...
(Date:5/6/2016)... FL (PRWEB) , ... May 06, 2016 , ... ... will feature AsedaSciences® in an upcoming episode, airing third quarter 2016, via Discovery ... the vision of becoming a leader in optimized drug discovery through innovative cellular ...
(Date:5/6/2016)... Grants Pass, OR (PRWEB) , ... May 06, 2016 , ... ... the eyes. In other seasons, when the weather is too cold, dry or hot, ... weather, the eyes can actually absorb moisture from the surrounding air. There’s only one ...
Breaking Medicine News(10 mins):